SLDB Solid Biosciences Inc.
Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
$3.68 -0.09 (-2.39%)
As of 03/24/2023 16:00:01 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Health Care
Industry: Drug Manufacturers—Specialty &
Index country: USA
Country of incorporation: USA
IPO date: 01/26/2018
Outstanding shares: 19,556,732
Average volume: 50,360
Market cap: $73,728,880
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: BQHN6C7
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%